DDInter1024 DDInter899
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Lapatinib {u} (Compound) treats {v} (Disease) breast cancer
Lapatinib {u} (Compound) binds {v} (Gene) TAP1
Lapatinib {u} (Compound) upregulates {v} (Gene) VAV3
Lapatinib {u} (Compound) downregulates {v} (Gene) PLOD3
Lapatinib {u} (Compound) causes {v} (Side Effect) Nail disorder
Lapatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Lapatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Propofol
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Lapatinib {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Lapatinib (Compound) treats breast cancer (Disease)
Lapatinib (Compound) binds TAP1 (Gene)
Lapatinib (Compound) upregulates VAV3 (Gene)
Lapatinib (Compound) downregulates PLOD3 (Gene)
Lapatinib (Compound) causes Nail disorder (Side Effect)
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Donepezil
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Propofol
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Lapatinib may lead to a major life threatening interaction when taken with Macimorelin